Core Viewpoint - Jinbo Biological has signed a share subscription agreement with Yangshengtang to issue shares aimed at integrating resources and advancing the industrialization of recombinant human collagen technology, marking a deep strategic partnership between the two companies [1][3] Group 1: Financial Details - Jinbo Biological plans to issue up to 7.18 million shares at a price of 278.72 RMB per share, raising a total of up to 2 billion RMB, with a lock-up period of 36 months [1] - If the 2 billion RMB private placement is successfully implemented, it will be the largest cash private placement in the history of the Beijing Stock Exchange [2] - The actual controller of Jinbo Biological, Yang Xia, has signed a transfer agreement with a subsidiary of Yangshengtang to transfer 5% of shares at a price of 243.84 RMB per share, totaling 1.4 billion RMB, which is also the largest transfer amount on the Beijing Stock Exchange [2] Group 2: Strategic Cooperation Benefits - The partnership will leverage Yangshengtang's extensive retail network, facilitating Jinbo Biological's product penetration into consumer markets, transitioning from professional medical applications to everyday health consumption [3] - Yangshengtang's large-scale industrial production system and supply chain management will enhance the efficiency of Jinbo Biological's technology transfer and shorten product launch cycles [3] - The collaboration will promote research applications of recombinant human collagen in serious medical fields, benefiting from Yangshengtang's strong R&D capabilities in vaccines and biomedicine [3] Group 3: Future Development Plans - The funds raised will primarily be used for the development of a FAST database and product development platform for human collagen, as well as to supplement working capital [4] - The strategic cooperation is expected to solidify Jinbo Biological's leadership in the recombinant human collagen sector and contribute to the high-quality development of China's biotechnology industry [4] - The partnership aims to provide competitive Chinese innovations to the global market and offer consumers better health solutions [4]
锦波生物引入战略投资者养生堂，共绘生物材料产业蓝图